Maria Lamar

1.3k total citations
16 papers, 323 citations indexed

About

Maria Lamar is a scholar working on Hepatology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Maria Lamar has authored 16 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hepatology, 4 papers in Pulmonary and Respiratory Medicine and 4 papers in Oncology. Recurrent topics in Maria Lamar's work include Hepatocellular Carcinoma Treatment and Prognosis (10 papers), Liver physiology and pathology (9 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Maria Lamar is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (10 papers), Liver physiology and pathology (9 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Maria Lamar collaborates with scholars based in United States, Italy and Germany. Maria Lamar's co-authors include Brian Schwartz, Armando Santoro, Giovanni Abbadessa, Lorenza Rimassa, Paolo Andrea Zucali, Matteo Simonelli, Ronald E. Savage, Bruno Daniele, Jordi Bruix and Camillo Porta and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Maria Lamar

16 papers receiving 318 citations

Peers

Maria Lamar

HEPAT

PFM

ONCOL

EPIDE

Annette Baumhauer Spain

Silvija Kraljevic United States

J. Zou United States

Kazuki Maesaka Japan

Guohong Han China

M Salvucci France

Kenichiro Kodama Japan

Yu-Jie Xu China

Songqiang Zhou China

Bing Quan China

Annette Baumhauer Spain

Maria Lamar

301 ×1.2

HEPAT

170 ×1.5

PFM

94 ×0.9

ONCOL

40 ×0.5

94 ×1.5

EPIDE

Citations per year, relative to Maria Lamar Maria Lamar (= 1×) peers Annette Baumhauer

Countries citing papers authored by Maria Lamar

Since Specialization

Citations

This map shows the geographic impact of Maria Lamar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Lamar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Lamar more than expected).

Fields of papers citing papers by Maria Lamar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Lamar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Lamar. The network helps show where Maria Lamar may publish in the future.

Co-authorship network of co-authors of Maria Lamar

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Lamar. A scholar is included among the top collaborators of Maria Lamar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Lamar. Maria Lamar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Rimassa, Lorenza, María Reig, Giovanni Abbadessa, et al.. (2017). Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma. World Journal of Gastroenterology. 23(13). 2448–2448. 10 indexed citations

Rimassa, Lorenza, Eric Assénat, Markus Peck‐Radosavljevic, et al.. (2017). Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.. Journal of Clinical Oncology. 35(15_suppl). 4000–4000. 33 indexed citations

Personeni, Nicola, Laura Giordano, Giovanni Abbadessa, et al.. (2017). Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 8(9). 14408–14415. 20 indexed citations

Rimassa, Lorenza, Giovanni Abbadessa, Nicola Personeni, et al.. (2016). Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 34(4_suppl). 197–197. 6 indexed citations

Rimassa, Lorenza, Giovanni Abbadessa, Nicola Personeni, et al.. (2016). Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib. Oncotarget. 7(45). 72622–72633. 51 indexed citations

Rimassa, Lorenza, Armando Santoro, Bruno Daniele, et al.. (2015). Tivantinib, a New Option for Second-line Treatment of Advanced Hepatocellular Carcinoma? The Experience of Italian Centers. Tumori Journal. 101(2). 139–143. 6 indexed citations

Puzanov, Igor, Jeffrey A. Sosman, Armando Santoro, et al.. (2014). Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Investigational New Drugs. 33(1). 159–168. 48 indexed citations

Saleh, MN, Fugui Chai, Maria Lamar, et al.. (2014). 320 First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphoma. European Journal of Cancer. 50. 104–104. 2 indexed citations

Santoro, Armando, Matteo Simonelli, Carlos Rodríguez de Lope, et al.. (2013). A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. British Journal of Cancer. 108(1). 21–24. 66 indexed citations

10.

Means‐Powell, Julie A., Alex A. Adjei, Igor Puzanov, et al.. (2012). Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.. Journal of Clinical Oncology. 30(15_suppl). 8519–8519. 11 indexed citations

11.

Puzanov, Igor, Jeffrey A. Sosman, Armando Santoro, et al.. (2012). Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.. Journal of Clinical Oncology. 30(15_suppl). 4545–4545. 4 indexed citations

12.

Chai, Fang, Giovanni Abbadessa, Ronald E. Savage, et al.. (2012). Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC). Annals of Oncology. 23. ix245–ix245. 4 indexed citations

13.

Rimassa, Lorenza, Camillo Porta, Ivan Borbath, et al.. (2012). Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).. Journal of Clinical Oncology. 30(15_suppl). 4006–4006. 25 indexed citations

14.

Martell, Robert E., Igor Puzanov, Wen Wee, et al.. (2012). Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.. Journal of Clinical Oncology. 30(15_suppl). 4117–4117. 15 indexed citations

15.

Adjei, Alex A., Jeffrey A. Sosman, Robert E. Martell, et al.. (2011). Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib.. Journal of Clinical Oncology. 29(15_suppl). 3034–3034. 8 indexed citations

16.

Zucali, Paolo Andrea, Armando Santoro, Carlos Rodríguez de Lope, et al.. (2010). Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 28(15_suppl). 4137–4137. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact